9 May 2023: Aker BioMarine ASA (the "Company") has renewed its offer of new
shares to employees in the Company and its Norwegian subsidiaries on similar
terms as for 2022 (the "Employee Share Purchase Program"). The deadline for
acceptance of the offer in the Employee Share Purchase Program expired today, on
9 May 2023, at 16:30 CET.

The offer price for the shares in the Employee Share Purchase Program has been
set to approximately NOK 29,81 (the "Offer Price"). The Offer Price is based on
the volume-weighted average share price for the Company's shares on the Oslo
Stock Exchange during the last five trading days prior to, and including, the
last day of the application period, with a discount of 20%. Any shares acquired
in the Employee Share Purchase Program will be subject to a lock-up period of
two years, and the reduced offer price shall reflect the value-reducing effect
of the lock-up period.

Based on the applications received in the Employee Share Purchase Program, the
board of directors of the Company has allocated a total of 35,015 new shares to
the participants in the Employee Share Purchase Program (the "Program Shares").

Furthermore, the board of directors has, on the basis of the authorisation
granted to it by the annual general meeting held on 20 April 2023, resolved to
increase the share capital of the Company with NOK 210 090, by issuance of 
35,015 new shares, each with a nominal value of NOK 6.00, at a subscription
price equal to the Offer Price. The Program Shares comprise approximately 0.04%
of the existing and outstanding shares in the Company prior to their issuance.

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret), the new share
capital of the Company will be NOK 526 036 488, divided into  87 672 748 shares,
each with a nominal value of NOK 6.00.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

For further information, please contact
Katrine Klaveness, CFO
Mobile: +47 991 58 915
Email: Katrine.Klaveness@akerbiomarine.com

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.